Christoph Hüls (born 1962) is Head of Technology Foresight & Scouting at Merck KGaA, Darmstadt, Germany. In his role, he is responsible for developing an innovation strategy and the first steps of its implementation towards new business for Merck. Previously he held different positions in the Chemical as well as the Healthcare sectors of Merck in new business development, licensing, corporate venture capital and operational excellence in R&D.
Prior to Merck, Christoph was chairmen of the Board of Protagen AG a German biotech company active in the development of software and services for the life science industry as well as diagnostics. Before that, Christoph was responsible for portfolio and project management within the generics division of Novartis. Christoph began his professional career at Hoechst AG in different responsibilities in pharmaceutical and chemical R&D. He studied Biology and received his PhD from the Johannes-Gutenberg University in Mainz at the Institute of Immunology.